128 related articles for article (PubMed ID: 34552008)
1. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.
Martin-Broto J; Lopez-Alvarez M; Moura DS; Ramos R; Collini P; Romagosa C; Bagué S; Renne SL; Barisella M; Velasco V; Coindre JM; Lopez-Lopez D; Dopazo J; Gambarotti M; Braglia L; Merlo DF; Palmerini E; Stacchiotti S; Quagliuolo VL; Lopez-Pousa A; Grignani G; Blay JY; Brunello A; Gutierrez A; Valverde C; Hindi N; Dei Tos AP; Picci P; Casali PG; Gronchi A
Mol Cancer Ther; 2021 Dec; 20(12):2539-2552. PubMed ID: 34552008
[TBL] [Abstract][Full Text] [Related]
2. MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
Martin-Broto J; Gutierrez AM; Ramos RF; Lopez-Guerrero JA; Ferrari S; Stacchiotti S; Picci P; Calabuig S; Collini P; Gambarotti M; Bague S; Dei Tos AP; Palassini E; Luna P; Cruz J; Cubedo R; Martinez-Trufero J; Poveda A; Casali PG; Fernandez-Serra A; Lopez-Pousa A; Gronchi A
Mol Cancer Ther; 2014 Jan; 13(1):249-59. PubMed ID: 24145283
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Pasquali S; Palmerini E; Quagliuolo V; Martin-Broto J; Lopez-Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz-Beveridge R; Ferraresi V; Lugowska I; Infante G; Braglia L; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Miceli R; Casali PG; Gronchi A
Cancer; 2022 Jan; 128(1):85-93. PubMed ID: 34643947
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Braglia L; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
J Clin Oncol; 2020 Jul; 38(19):2178-2186. PubMed ID: 32421444
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.
Villar VH; Vögler O; Martínez-Serra J; Ramos R; Calabuig-Fariñas S; Gutiérrez A; Barceló F; Martín-Broto J; Alemany R
PLoS One; 2012; 7(5):e37735. PubMed ID: 22662203
[TBL] [Abstract][Full Text] [Related]
6. Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.
Villar VH; Vögler O; Barceló F; Gómez-Florit M; Martínez-Serra J; Obrador-Hevia A; Martín-Broto J; Ruiz-Gutiérrez V; Alemany R
J Nutr Biochem; 2014 Apr; 25(4):429-38. PubMed ID: 24491315
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
8. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
9. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
10. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
11. Treating soft tissue sarcomas with adjuvant chemotherapy.
Patrikidou A; Domont J; Cioffi A; Le Cesne A
Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
[TBL] [Abstract][Full Text] [Related]
12. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
14. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.
Frezza AM; Stacchiotti S; Chibon F; Coindre JM; Italiano A; Romagnosa C; Bagué S; Dei Tos AP; Braglia L; Palmerini E; Quagliuolo V; Broto JM; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Beveridge RD; Lugowska I; Lesluyes T; Maestro R; Merlo FD; Casali PG; Gronchi A
Cancer Med; 2023 Jan; 12(2):1350-1357. PubMed ID: 35848358
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young RJ; Litière S; Lia M; Hogendoorn PCW; Fisher C; Mechtersheimer G; Daugaard S; Sciot R; Collin F; Messiou C; Grünwald V; Gronchi A; van der Graaf W; Wardelmann E; Judson I
Acta Oncol; 2017 Jul; 56(7):1013-1020. PubMed ID: 28431480
[TBL] [Abstract][Full Text] [Related]
16. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
17. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A; Frustaci S; Mercuri M; Martin J; Lopez-Pousa A; Verderio P; Mariani L; Valagussa P; Miceli R; Stacchiotti S; Dei Tos AP; De Paoli A; Longhi A; Poveda A; Quagliuolo V; Comandone A; Casali PG; Picci P
J Clin Oncol; 2012 Mar; 30(8):850-6. PubMed ID: 22312103
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience.
Brunello A; Rizzato MD; Rastrelli M; Roma A; Maruzzo M; Basso U; Fiduccia P; Buzzaccarini MS; Scarzello G; Rossi CR; Zagonel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):679-85. PubMed ID: 26547435
[TBL] [Abstract][Full Text] [Related]
19. What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
Hindi N; Martin-Broto J
Curr Opin Oncol; 2021 Jul; 33(4):329-335. PubMed ID: 33973551
[TBL] [Abstract][Full Text] [Related]
20. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A; Stacchiotti S; Verderio P; Ferrari S; Martin Broto J; Lopez-Pousa A; Llombart-Bosch A; Dei Tos AP; Collini P; Jurado JC; De Paoli A; Donati DM; Poveda A; Quagliuolo V; Comandone A; Grignani G; Morosi C; Messina A; De Sanctis R; Bottelli S; Palassini E; Casali PG; Picci P
Ann Oncol; 2016 Dec; 27(12):2283-2288. PubMed ID: 27733375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
